Beam Therapeutics (BEAM)

Company Profile

Beam Therapeutics is a biotechnology company committed to establishing the leading, fully integrated platform for precision genetic medicines. To achieve this vision, Beam has assembled a platform that includes a suite of gene editing and delivery technologies and is in the process of building internal manufacturing capabilities. Beam's suite of gene editing technologies is anchored by base editing, a proprietary technology that enables precise, predictable and efficient single base changes, at targeted genomic sequences, without making double-stranded breaks in the DNA. This enables a wide range of potential therapeutic editing strategies that Beam is using to advance a diversified portfolio of base editing programs. Beam is a values-driven organization committed to its people, cutting-edge science, and a vision of providing life-long cures to patients suffering from serious diseases.

Company profile

Ticker

BEAM

Exchange

NASDAQ

Website

beamtx.com

CEO

John M. Evans

Incorporated

Delaware

Location

Massachusetts

Fiscal year end

Dec 31

Sector

Manufacturing > Biological Product (except Diagnostic) Manufacturing

Industry (SIC)

Biological Products, (No Diagnostic Substances)

AMGEN • Gilead Sciences • Biogen • Qiagen • Moderna • BioNTech SE • Sana Biotechnology • Bio-Techne • Exelixis • Ginkgo Bioworks ...

SEC CIK

0001745999

Corporate docs

Articles of Incorporation & Bylaws

Underwriting Agreements

Plans of Reorganization

Indentures

Material Contracts & Credit Agreements

Subsidiaries Lists

Subsidiaries

Beam Therapeutics Securities Corporation • Guide Therapeutics, LLC ...

BEAM stock data

1M 1Y 5Y

Analyst ratings and price targets

Last 3 months

Average target

$81.33

Low target

$62.00

High target

$105.00

Latest filings (excl ownership)

View all

S-8

Registration of securities for employees

28 Feb 23

Beam Therapeutics Reports Fourth Quarter and Year-End 2022 Financial Results and Reiterates Anticipated Milestones

28 Feb 23

8-K

Results of Operations and Financial Condition

7 Nov 22

Beam Therapeutics Announces Portfolio Progress and Reports Third Quarter 2022 Financial Results

9 Aug 22

Beam Therapeutics Announces Pipeline and Business Highlights and Reports Second Quarter 2022 Financial Results

9 Aug 22

Latest ownership filings

View all

SC 13G

Temasek Holdings (Private) Ltd

17 Mar 23

SC 13G/A

Farallon Capital Partners, L.P.

14 Feb 23

SC 13G/A

ARK Investment Management LLC

10 Feb 23

SC 13G/A

Temasek Holdings (Private) Ltd

Financial summary

Financial statements Chart BEAM financial data

Quarter (USD)	Dec 22	Sep 22	Jun 22	Mar 22
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Annual (USD)	Dec 22	Dec 21	Dec 20	Dec 19
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Cash burn rate (est.)	Burn method: Change in cash		Burn method: Operating income		Burn method: FCF (opex + capex)
	Last Q	Avg 4Q	Last Q	Avg 4Q	Last Q	Avg 4Q
Cash on hand (at last report)	245.52 mm	245.52 mm	245.52 mm	245.52 mm	245.52 mm	245.52 mm
Cash burn (monthly)	(no burn)	27.27 mm	29.66 mm	28.21 mm	23.06 mm	(no burn)
Cash used (since last report)	n/a	73.36 mm	79.80 mm	75.89 mm	62.05 mm	n/a
Cash remaining	n/a	172.16 mm	165.72 mm	169.63 mm	183.47 mm	n/a
Runway (months of cash)	n/a	6.3	5.6	6.0	8.0	n/a

Beta Read what these cash burn values mean

Financial data from company earnings reports.

Institutional ownership, Q4 2022

BEAM institutional ownership history Ownership history

89.7% owned by funds/institutions

13F holders	Current	Prev Q	Change
Total holders	210	220	-4.5%
Opened positions	28	47	-40.4%
Closed positions	38	27	+40.7%
Increased positions	84	70	+20.0%
Reduced positions	55	64	-14.1%

13F shares	Current	Prev Q	Change
Total value	2.17 tn	2.61 bn	+83091.8%
Total shares	64.92 mm	60.66 mm	+7.0%
Total puts	382.70 k	235.20 k	+62.7%
Total calls	191.70 k	726.70 k	-73.6%
Total put/call ratio	2.0	0.3	+516.8%

Largest owners	Shares	Value	Change
ARK Investment Management	8.21 mm	$321.22 bn	-3.3%
Vanguard	6.27 mm	$245.36 bn	+1.6%
ARCH Venture Fund IX	5.84 mm	$0.00	0.0%
BLK Blackrock	5.24 mm	$204.88 bn	-2.4%
FMR	4.97 mm	$194.22 bn	+8.3%
Farallon Capital Management	3.40 mm	$132.97 bn	-6.4%
Farallon Capital Partners	3.25 mm	$0.00	-4.6%
STT State Street	3.09 mm	$121.00 bn	NEW
Temasek	2.88 mm	$112.57 bn	+0.4%
MWG Management	2.35 mm	$91.79 bn	0.0%

Largest transactions	Shares	Bought/sold	Change
STT State Street	3.09 mm	+3.09 mm	NEW
Norges Bank	498.01 k	+498.01 k	NEW
FMR	4.97 mm	+381.85 k	+8.3%
ARK Investment Management	8.21 mm	-277.81 k	-3.3%
Farallon Capital Management	3.40 mm	-231.35 k	-6.4%
Capital Research Global Investors	227.57 k	+227.57 k	NEW
Two Sigma Investments	0.00	-199.00 k	EXIT
Ubs Global Asset Management Americas	248.50 k	+189.71 k	+322.7%
Voloridge Investment Management	46.00 k	-168.22 k	-78.5%
Deep Track Capital	1.17 mm	+166.47 k	+16.6%

Data from 13F filings, for the last complete 13F reporting period. For most recent data, click the ownership history button. Values as filed, not updated for current price. Long positions only.

Recent insider trades

BEAM insider ownership history Insider history

Date	Owner	Security	Transaction	Code	Indirect	10b5-1	$Price	#Shares	$Value	#Remaining
27 Jan 23	Terry-Ann Burrell	Common Stock	Sell	Dispose S	No	Yes	45.0804	36,152	1.63 mm	31,277
27 Jan 23	Terry-Ann Burrell	Common Stock	Option exercise	Acquire M	No	Yes	13.68	36,152	494.56 k	67,429
27 Jan 23	Terry-Ann Burrell	Stock Option Common Stock	Option exercise	Dispose M	No	Yes	13.68	36,152	494.56 k	185,565
26 Jan 23	Terry-Ann Burrell	Common Stock	Sell	Dispose S	No	Yes	45.1572	1,102	49.76 k	31,277
26 Jan 23	Terry-Ann Burrell	Common Stock	Option exercise	Acquire M	No	Yes	13.68	1,102	15.08 k	32,379
26 Jan 23	Terry-Ann Burrell	Stock Option Common Stock	Option exercise	Dispose M	No	Yes	13.68	1,102	15.08 k	221,717
24 Jan 23	Terry-Ann Burrell	Common Stock	Sell	Dispose S	No	Yes	45.014	14,810	666.66 k	31,277
24 Jan 23	Terry-Ann Burrell	Common Stock	Option exercise	Acquire M	No	Yes	13.68	14,810	202.60 k	46,087
24 Jan 23	Terry-Ann Burrell	Stock Option Common Stock	Option exercise	Dispose M	No	Yes	13.68	14,810	202.60 k	222,819
23 Jan 23	Terry-Ann Burrell	Common Stock	Sell	Dispose S	No	Yes	45.0221	5,426	244.29 k	31,277